This article is freely available to all

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: The limitations of the current medications used to treat schizophrenia have led to a search for adjunctive treatments that may better address the negative symptoms, cognitive deficits, and behavioral problems of the disorder. A promising strategy might be adopted from the current use of acetylcholinesterase inhibitors in the treatment of Alzheimer’s disease.1 Acetylcholinesterase inhibitors (e.g., tacrine, donepezil) improve general cognitive functioning and reduce apathy, anxiety, agitation, and other psychiatric symptoms in Alzheimer’s patients.